Who Paid My Doc
Thomas McGarry
Interventional Cardiology Oklahoma City, OK Medical Doctor
NPI 1427045400 CMS profile 64746
4050 W Memorial Rd Fl 3, Oklahoma City, OK 73120
General payments
$79,561
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$73,242
Through program year 2025, Thomas McGarry of Oklahoma City, OK is reported in the CMS Open Payments database as having received $79,561 across 69 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $73,242 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 90th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $14,537 | 19 | |
| 2024 | General | $7,200 | 3 | |
| 2023 | General | $12,379 | 12 | |
| 2022 | General | $6,582 | 4 | |
| 2021 | General | $15,001 | 11 | |
| 2020 | General | $10,335 | 8 | |
| 2019 | General | $13,528 | 12 |
Beside peers
- Thomas McGarry
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to Thomas McGarry were reported at $14,537. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | Thomas McGarry | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $13,528 | $1,097 | $329–$3,048 | $163 |
| 2020 | $10,335 | $473 | $161–$1,480 | $114 |
| 2021 | $15,001 | $677 | $233–$1,827 | $132 |
| 2022 | $6,582 | $978 | $333–$2,724 | $149 |
| 2023 | $12,379 | $1,136 | $382–$2,986 | $160 |
| 2024 | $7,200 | $1,181 | $395–$3,326 | $164 |
| 2025 | $14,537 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 67 drugsPart D claims
11,066
Drug cost
$1,015,500
Branded share of claims
18%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 536 | $472,947 | |
| Xarelto Rivaroxaban | Brand | 222 | $208,067 | |
| Repatha Sureclick Evolocumab | Brand | 116 | $80,390 | |
| Entresto Sacubitril/Valsartan | Brand | 45 | $54,774 | |
| Metoprolol Succinate | Generic | 2,199 | $36,824 | |
| Praluent Pen Alirocumab | Brand | 23 | $16,740 | |
| Atorvastatin Calcium | Generic | 961 | $14,225 | |
| Brilinta Ticagrelor | Brand | 22 | $10,222 | |
| Losartan Potassium | Generic | 648 | $8,472 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 488 | $8,185 |
The 10 drugs with the highest cost, of 67 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 60 billing codesPaid by Medicare
$328,952
Medicare patients
1,428
Services billed
4,341
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 63% | |
| Arthritis | 51% | |
| Heart failure | 37% | |
| Diabetes | 34% | |
| Atrial fibrillation | 29% | |
| Chronic kidney disease | 24% | |
| COPD | 16% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
69 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Interventional Cardiology in Oklahoma
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Oklahoma
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.